Nektar Therapeutics reports results for the quarter ended March 31 - Earnings Summary

Nektar Therapeutics

08/05/2025 22:53

Nektar Therapeutics NKTR.OQ reported a quarterly adjusted loss of 24 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -19 cents.  The mean expectation of eight analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -19 cents to -9 cents per share.

Revenue fell 51.7% to $10.45 million from a year ago; analysts expected $15.36 million.

Nektar Therapeutics's reported EPS for the quarter was a loss of 24 cents​.

The company reported a quarterly loss of $50.88 million.

Nektar Therapeutics shares had fallen by 10.9% this quarter and lost 34.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 18.8% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Nektar Therapeutics is $5.00

This summary was machine generated from LSEG data May 8 at 09:52 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.16
-0.24
Missed
Dec. 31 2024
-0.17
-0.16
Beat
Sep. 30 2024
-0.21
-0.18
Beat
Jun. 30 2024
-0.20
-0.25
Missed